Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation

GlobeNewswire March 23, 2022

Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference

GlobeNewswire March 22, 2022

Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results

GlobeNewswire March 16, 2022

Synthetic Biologics Completes Acquisition of VCN Biosciences

GlobeNewswire March 11, 2022

Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial Results

GlobeNewswire March 10, 2022

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference

PR Newswire February 9, 2022

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

PR Newswire February 8, 2022

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022

PR Newswire January 26, 2022

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

PR Newswire December 14, 2021

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

PR Newswire November 3, 2021

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021

PR Newswire October 26, 2021

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase

PR Newswire October 21, 2021

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

PR Newswire October 6, 2021

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

PR Newswire September 21, 2021

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

PR Newswire August 5, 2021

Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital

PR Newswire August 3, 2021

Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021

PR Newswire July 28, 2021

Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial

PR Newswire June 29, 2021

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

PR Newswire May 26, 2021

Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results

PR Newswire May 5, 2021